Clinical Trial Update: T900607 in Treating Patients With Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the agent T900607 in patients with gastric cancer and gastroesophageal junction cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• T900607

Snippet

Sponsor: University Hospitals Seidman Cancer Center | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED